GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (NAS:SCYX) » Definitions » EV-to-EBIT

SCYNEXIS (SCYNEXIS) EV-to-EBIT : -0.04 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SCYNEXIS's Enterprise Value is $-2.7 Mil. SCYNEXIS's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $70.3 Mil. Therefore, SCYNEXIS's EV-to-EBIT for today is -0.04.

The historical rank and industry rank for SCYNEXIS's EV-to-EBIT or its related term are showing as below:

SCYX' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.41   Med: -1.09   Max: 2.22
Current: -0.04

During the past 12 years, the highest EV-to-EBIT of SCYNEXIS was 2.22. The lowest was -13.41. And the median was -1.09.

SCYX's EV-to-EBIT is ranked better than
98.95% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.125 vs SCYX: -0.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SCYNEXIS's Enterprise Value for the quarter that ended in Dec. 2023 was $23.7 Mil. SCYNEXIS's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $70.3 Mil. SCYNEXIS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 296.77%.


SCYNEXIS EV-to-EBIT Historical Data

The historical data trend for SCYNEXIS's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS EV-to-EBIT Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.05 -1.35 -3.43 -0.42 0.34

SCYNEXIS Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -1.10 0.78 0.15 0.34

Competitive Comparison of SCYNEXIS's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's EV-to-EBIT falls into.



SCYNEXIS EV-to-EBIT Calculation

SCYNEXIS's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-2.652/70.309
=-0.04

SCYNEXIS's current Enterprise Value is $-2.7 Mil.
SCYNEXIS's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $70.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SCYNEXIS  (NAS:SCYX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SCYNEXIS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=70.309/23.691394
=296.77 %

SCYNEXIS's Enterprise Value for the quarter that ended in Dec. 2023 was $23.7 Mil.
SCYNEXIS's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $70.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SCYNEXIS EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (SCYNEXIS) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Executives
David C Hastings director C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Brian Philippe Tinmouth director 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Armando Anido director 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
Scott Sukenick officer: General Counsel 101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Lawrence R Hoffman officer: Interim CFO C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087
Christine Coyne officer: Chief Commercial Officer 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric Francois officer: Chief Financial Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Gonzalez David Angulo officer: Chief Medical Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713

SCYNEXIS (SCYNEXIS) Headlines

From GuruFocus